Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1775 plus carboplatin in p53-mutated platinum-refractory or early-relapsed solid tumors
NL-OMON47848Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of adavosertib and carboplatin in ovarian cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and 2 more (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Safety and preliminary antitumor activity in phase II POP trial and Safety and preliminary antitumor activity in additional cohorts. Started Nov 2010; status: active, not recruiting.
02
Drugs
adavosertibcarboplatin
03
Conditions
ovarian cancernon-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)Cervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON47848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47848.